Clinical Publications Citing VerifyNow P2Y12 Test:
| Author(s) | Title and Reference |
|---|---|
| Ang L, et al. | Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008 Sep 23;52(13):1052-9. |
| Angiolillo DJ, et al. | Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16. |
| Angiolillo DJ, et al. | Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol. 2008 Feb 15;101(4):440-5. |
| Angiolillo DJ, et al. | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008 Sep;29(18):2202-11. |
| Bonello, et al. | Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. J Am Coll Cardiol. 2008 Apr 8;51(14):1404-11. |
| Buonamici, et al | Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. |
| Chen L, et al. | Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004 Sep;128(3):425-31. |
| Collet JP, et al. | Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation. 2008 Sep 16;118(12):1225-33. Epub 2008 Sep 2. Erratum in: Circulation.2008 Oct 14;118(16): e672. Comment in: Circulation. 2008 Sep 16;118(12):1219-22. |
| Cuisset T, et al. | Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol. 2008 Jun 15;101(12):1700-3. |
| Dupont, et al | Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research. 2009;124(1):6-13 |
| Gladding P, et al. | The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial. J Am Coll Cardiol Intv. 2008 Dec;1:620-27 |
| Gurbel P, et al. | Clopidogrel resistance? Thromb Res. 2007;120(3):311-21. |
| Gurbel P, et al. | Platelet Function Monitoring in Patients with Coronary Artery Disease. J Am Coll Cardiol. 2007 Nov 6;50(19):1822-34. |
| Hobson AR, et al. | Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J. 2008 Feb 29;6:1. |
| Jakubowski JA, et al. | Effect of prasugrel and high dose clopidogrel on platelet function as assessed by point-of-care and optical aggregometry. J Thromb Haemost 2007; 5 Supplement 2: P-S-346 |
| Jakubowski JA, et al. | The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. J Thromb Haemost. 2008 Feb;99(2):409-15. |
| Jeong YH, et al. | The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J. 2008 Jul 9. |
| Jeong YH, et al. | Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 2009 Mar 31;53(13):1101-9. |
| Lee DH, et al. | Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. Am J Neuroradiol. 2008 Aug;29(7):1389-94. |
| Lev EI, et al. | Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006 Jan 3;47(1):27-33. |
| Lordkipanidzé M, et al. | Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J. 2008 Dec;29(23):2877-85 |
| Lordkipanidzé M, et al. | Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther Drug Monit. 2008 Jun;30(3):372-8. |
| Malinin A, et al. | Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22. |
| Malinini A, et al. | Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res. 2007;119(3):277-84. |
| Marcucci, et al | Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Plalelet Reactivity to ADP Detected by a POC Assay. A 12-Month Follow-up Circulation. 2009 Jan 20;119(2):237-42. |
| McLean DS, et al. | A point of care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3): 255-267. |
| McLean DS, et al. | The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Critical Pathways in Cardiology. 2006; 5(2): 103–113. |
| Muller-Schunk S, et al. | Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-aortic Stenting. Am J Neuroradiol. 2008 Apr;29(4):786-91 |
| Patti G, et al. | Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33. |
| Prabhakaran S, et al. | Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting. Am J Neuroradiol. 2008 Feb;29(2):281-5. |
| Price MJ, et al. | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000. Comment in: Eur Heart J. 2008 Apr;29(8):957-8. Eur Heart J. 2008 Jun;29(11):1471; author reply 1471-2. |
| Price MJ, et al. | Onset and offset of platelet Inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006 Sep 1;98(5):681-4. |
| Price MJ, et al. | Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol. 2008 Sep 15;102(6):790-5. |
| Price MJ. | Emerging concepts in the response to antiplatelet therapy. Cath Lab Digest. 2006; 14(1): 1-7. |
| Price MJ, et al. | Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. American Heart Journal. 2009;157:818-824 |
| Price MJ, et al. | Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009 May 15;103(10):1339-43 |
| Saw J, et al. | The Effects of Aspirin and Clopidogrel Response on Myonecrosis After Percutaneous Coronary Intervention: A BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) Trial Substudy. J Am Coll Cardiol Intv. 2008 Dec;1:654-59. |
| Saw J, et al. | The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol. 2008 Dec 2;52(23):1826-33. |
| Serebruany V, et al. | Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost. 2008 Jul;100(1):76-82. |
| Serebruany VL, et al. | Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005 Jan 18;45(2):246-51. |
| Serebruany VL, et al. | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008 Jan;155(1):93.e1-7. Comment in: Am Heart J. 2008 Jun;155(6):e47; author reply e49 |
| Serebruany VL, et al. | Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J. 2006 Jun;82(968):404-10. |
| Shim CY, et al. | The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol. 2009 May 29;134(3):351-5. |
| Tourmousoglou CE, et al. | Clopidogrel and aspirin in cardiovascular medicine: responders or not - current best available evidence. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):312-22. |
| van Werkum JW, et al. | A head-to-head comparison between the VerifyNowP2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost. 2006 Nov;4(11):2516-8. |
| van Werkum JW, et al. | The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008 Nov;19(7):479-88. |
| Varenhorst C, et al. | Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J. 2009 Mar;157(3):562.e1-9. |
| von Beckerath N, et al. | A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost. 2005 Apr;93(4):789-91. |
| von Beckerath N, et al. | A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30 days. Eur Heart J. 2008 Feb;29(3):423-4. |
| von Beckerath N, et al. | Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. J Thromb Haemost. 2006 May;95(5):910-1. |
| Wang TH, et al. | Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006 Mar;27(6):647-54. |
| Wiviott S, et al. | Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation. 2007 Dec 18;116(25):2923-32. |
| Wiviott S, et al. | Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18;116(25):2923-32. |
